REFERENCES
1. Demidov L, Samoylenko I, Kharkevich G, et al. Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: results from the phase III OCTAVA trial. Eur J Cancer. 2025;227:115674.
2. Jahangir M, Yazdani O, Kahrizi MS, et al. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell Int. 2022;22:401.
3. Wang Q, Li X, Qiu J, et al. A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. Comput Struct Biotechnol J. 2023;21:2536-46.
4. Lim SY, Shklovskaya E, Lee JH, et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2023;14:1516.
5. Gambichler T, Finis C, Abu Rached N, et al. Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2023;149:1241-7.
6. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020-31.
7. Mahoney KM, Ross-Macdonald P, Yuan L, et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immunother Cancer. 2022;10:e003527.
8. Hu Y, Zhou Y, Zhang M, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995-1007.
9. Missiaen R, Lesner NP, Simon MC. HIF: a master regulator of nutrient availability and metabolic cross-talk in the tumor microenvironment. EMBO J. 2023;42:e112067.
10. Jin M, Cao W, Chen B, Xiong M, Cao G. Tumor-derived lactate creates a favorable niche for tumor via supplying energy source for tumor and modulating the tumor microenvironment. Front Cell Dev Biol. 2022;10:808859.
11. Zalpoor H, Aziziyan F, Liaghat M, et al. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Commun Signal. 2022;20:186.
12. Flies DB, Langermann S, Jensen C, Karsdal MA, Willumsen N. Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix. Front Immunol. 2023;14:1199513.
13. Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:70.
14. Wang T, Wang J, Jiang H, et al. Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments. Mater Today Bio. 2022;15:100304.
15. Sattiraju A, Kang S, Giotti B, et al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity. 2023;56:1825-1843.e6.
16. Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020.
17. Ma L, Hostetler A, Morgan DM, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148-3165.e20.
18. Wang Y, Drum DL, Sun R, et al. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. Nat Commun. 2023;14:5727.
19. Cao Z, Li D, Zhao L, et al. Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery. Nat Commun. 2022;13:2038.
20. Chen Y, Huang Y, Li Q, et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023;18:193-204.
21. Li J, Luo Y, Zeng Z, et al. Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. Nat Commun. 2022;13:4032.
22. Liu L, Pan D, Chen S, et al. Systematic design of cell membrane coating to improve tumor targeting of nanoparticles. Nat Commun. 2022;13:6181.
23. Zelepukin IV, Griaznova OY, Shevchenko KG, et al. Flash drug release from nanoparticles accumulated in the targeted blood vessels facilitates the tumour treatment. Nat Commun. 2022;13:6910.
24. Hao Y, Gao Y, Fan Y, et al. A tumor microenvironment-responsive poly(amidoamine) dendrimer nanoplatform for hypoxia-responsive chemo/chemodynamic therapy. J Nanobiotechnology. 2022;20:43.
25. Song J, Cheng M, Xie Y, Li K, Zang X. Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug. J Nanobiotechnology. 2023;21:93.
26. Tang J, Zhang X, Cheng L, et al. Multiple stimuli-responsive nanosystem for potent, ROS-amplifying, chemo-sonodynamic antitumor therapy. Bioact Mater. 2022;15:355-71.
27. Tang M, Chen B, Xia H, et al. pH-gated nanoparticles selectively regulate lysosomal function of tumour-associated macrophages for cancer immunotherapy. Nat Commun. 2023;14:5888.
28. Wang Y, Wang Q, Wang X, et al. Docetaxel-loaded pH/ROS dual-responsive nanoparticles with self-supplied ROS for inhibiting metastasis and enhancing immunotherapy of breast cancer. J Nanobiotechnology. 2023;21:286.
29. Mao D, Li B, Li J, Pan J, Wu Z, Feng N. Nanodrug delivery systems in tumor immunotherapy: From immune activation to tumor reprogramming. Adv Drug Deliv Rev. 2026;232:115838.
30. He J, Xue W, Li Y. Tumor microenvironment-responsive nanomedicine: monitoring and modulating the tumor microenvironment for precision cancer therapy. Int J Nanomedicine. 2026;21:560983.
31. Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11:24.
32. Cressey P, Abd Shukor SB, Thanou M. Sonodynamic therapy: transforming sound into light for hard-to-treat tumours. Adv Drug Deliv Rev. 2025;226:115696.
33. Yuan F, Peng D, Lu M, Zhang K, Mi P, Xu J. Ultrasound-responsive nanocarriers for cancer therapy: Physiochemical features-directed design. J Control Release. 2025;388:114353.
34. Bano I, Jorratt P, Kútna V, Pala J, Tsenov G. Noninvasive focused ultrasound as a safe modulator of calcium-dependent neurochemical signalling in primary cortical cultures. Neurochem Res. 2026;51:61.
35. Kojima Y. Effects of low-intensity pulsed ultrasound on muscle mass and Fndc5 mRNA expression in aged male mice. Biogerontology. 2025;26:187.
36. Ayyami Y, Dastgir M, Yektamanesh M, et al. Advances in ultrasound-activated nano-sonosensitizers for cancer treatment: a systematic review and meta-analysis. Ultrason Sonochem. 2026;127:107750.
37. Kong C, Luo C, Xue F, et al. Ultrasound-triggered charge-reversal nanoparticles via golgi-dependent iterative transcytosis for enhanced deep tumor penetration. ACS Nano. 2026;20:4741-57.
38. Liang G, Sadhukhan T, Banerjee S, et al. Reduction of platinum(IV) prodrug hemoglobin nanoparticles with deeply penetrating ultrasound radiation for tumor-targeted therapeutically enhanced anticancer therapy. Angew Chem Int Ed Engl. 2023;62:e202301074.
39. Chen Y, Du M, Yuan Z, Chen Z, Yan F. Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy. Nat Commun. 2022;13:4468.
40. Fabiano AR, Newman MW, Dombroski JA, et al. Applying ultrasound to mechanically and noninvasively sensitize prostate tumors to TRAIL-mediated apoptosis. Adv Sci (Weinh). 2025;12:e2412995.
41. Pepple AL, Guy JL, McGinnis R, et al. Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. Front Immunol. 2023;14:1012799.
42. Wu Y, Huang Z, Liu Y, et al. Ultrasound control of genomic regulatory toolboxes for cancer immunotherapy. Nat Commun. 2024;15:10444.
43. He J, Liu Z, Zhu X, Xia H, Gao H, Lu J. Ultrasonic microbubble cavitation enhanced tissue permeability and drug diffusion in solid tumor therapy. Pharmaceutics. 2022;14:1642.
44. Imran KM, Tintera B, Morrison HA, et al. Improved therapeutic delivery targeting clinically relevant orthotopic human pancreatic tumors engrafted in immunocompromised pigs using ultrasound-induced cavitation: a pilot study. Pharmaceutics. 2023;15:1585.
45. Luo Y, Qiao B, Yang C, et al. Low intensity focused ultrasound ignited “deep-penetration nanobomb” (DPNB) for tetramodal imaging guided hypoxia-tolerant sonodynamic therapy against hypoxic tumors. Int J Nanomedicine. 2022;17:4547-65.
46. Ye D, Wang G, Liu X, et al. Cascade ultrasonic cavitation enables microbubble-nanoparticle hybrid to broadly accumulate and penetrate into pancreatic ductal adenocarcinoma. Small Structures. 2025;6:2500077.
47. Chen Y, Song Y, Zhang C, et al. Ultrasound-responsive release of CD39 inhibitor overcomes adenosine-mediated immunosuppression in triple-negative breast cancer. J Control Release. 2025;383:113819.
48. Fang M, Zheng J, Song Q, et al. Breaking apoptosis-induced immune silence: ultrasound-activated nano-oncolytic therapy reinvigorates antitumor immunity. Adv Mater. 2025;37:e2508681.
49. Yang J, Liao M, Wu Z, et al. Perfluorohexane nanodroplet-assisted mechanical high intensity focused ultrasound cavitation: a strategy for hepatocellular carcinoma treatment. Acta Biomater. 2025;195:297-308.
50. Bhalotia A, Hutchinson DW, Kosmides T, et al. Enhanced delivery of lipid nanoparticle-based immunotherapy by modulating the tumor tissue stiffness using ultrasound-activated nanobubbles. ACS Nano. 2026;20:4592-606.
51. Chen L, Liu J, Chen Q, et al. Modulating tumor interstitial fluid pressure using ultrasound and microbubble therapy: a preclinical study for enhanced drug delivery in cancer treatment. BMC Cancer. 2025;26:40.
52. Yang G, Li H, Yin J, et al. Alleviating tumor hypoxia and immunosuppression via sononeoperfusion: a new ally for potentiating anti-PD-L1 blockade of solid tumor. Ultrason Sonochem. 2025;112:107115.
53. Jiang Z, Xiao W, Fu Q. Stimuli responsive nanosonosensitizers for sonodynamic therapy. J Control Release. 2023;361:547-67.
54. Chen F, Zhang H, Li S, et al. Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy. Nat Commun. 2025;17:272.
55. Tang J, Chen Y, Lai H, et al. Innovative immunosonogen nanoplatform combining sonodynamic oxygenation and immunomodulation for superior cancer therapy. Chem Eng J. 2025;515:163582.
56. Xue H, Jin J, Huang X, et al. Wearable flexible ultrasound microneedle patch for cancer immunotherapy. Nat Commun. 2025;16:2650.
57. Yang M, Zhang W, Su L, et al. Biomimetic nanoadjuvant-enhanced ultrasound-induced STING activation potentiates aPD-L1 therapy to overcome cancer recurrence and metastasis. Chem Eng J. 2025;511:161735.
58. Ma K, Dong J, Chen Z, et al. Ultrasound-powered piezocatalytic nanomotors with dual-mode synergistic/cascade propulsion reprogram hypoxic tumor-associated macrophages for enhanced cancer immunotherapy. Chem Eng J. 2025;512:162107.
59. Wang C, Zhang R, He J, et al. Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. Nat Commun. 2023;14:3877.
60. Ren S, Zhang M, Cai C, et al. A carrier-free ultrasound-responsive polyphenol nanonetworks with enhanced sonodynamic-immunotherapy for synergistic therapy of breast cancer. Biomaterials. 2025;317:123109.
61. McCorkell G, Nakayama M, Feltis B, Piva T, Geso M. Ultrasound-stimulated microbubbles enhance radiation-induced cell killing. Ultrasound Med Biol. 2022;48:2449-60.
62. Du JR, Wang Y, Yue ZH, et al. Recent advances in sonodynamic immunotherapy. J Cancer Res Clin Oncol. 2023;149:1645-56.
63. Tao Y, Zhuang W, Fan W, et al. Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment. iScience. 2025;28:111858.
64. Zhaoyun L, Wang H, Yang C, et al. Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma. J Immunother Cancer. 2025;13:e011717.
65. Fite BZ, Wang J, Kare AJ, et al. Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer. Sci Rep. 2021;11:927.
66. Akter S, Madhuvilakku R, Kar AK, et al. Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications. Signal Transduct Target Ther. 2026;11.
67. Wu X, Liang J, Shu J, et al. Narrow-bandgap iridium(III)-C3N5 nanocomplex as an oxygen self-sufficient piezo-sonosensitizer for hypoxic tumor sonodynamic immunotherapy. J Am Chem Soc. 2025;147:15329-43.
68. Zhang L, Yi H, Song J, et al. Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced deep-penetration sonodynamic cancer therapy. ACS Appl Mater Interfaces. 2019;11:9355-66.
69. Lei Q, Zhou W, Gao S, et al. Ultrasound-responsive metal-organic framework-based nanosystem for sonodynamic therapy/amplified ferroptosis/IDO-blockade osteosarcoma immunotherapy. Chem Eng J. 2024;490:151614.
70. Wang Q, He J, Qi Y, Ye Y, Ye J, Zhou M. Ultrasound-enhanced nano catalyst with ferroptosis-apoptosis combined anticancer strategy for metastatic uveal melanoma. Biomaterials. 2024;305:122458.
71. Zheng H, Lin H, Ke Y, et al. Piezoelectric-triggered ferroptosis for cancer therapy via cascade-enhanced immune response. Adv Healthc Mater. 2025;14:e2501339.
72. Rucker AJ, Park CS, Li QJ, Moseman EA, Chan FK. Necroptosis stimulates interferon-mediated protective anti-tumor immunity. Cell Death Dis. 2024;15:403.
73. Mannion J, Gifford V, Bellenie B, et al. A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity. 2024;57:1514-1532.e15.
74. Zuo Z, Yin H, Zhang Y, Xie C, Wang Q. A cytotoxic T cell inspired oncolytic nanosystem promotes lytic cell death by lipid peroxidation and elicits antitumor immune responses. Nat Commun. 2023;14:5456.
75. Lv Z, Liu Z, Nie Z, et al. Ferroptosis reshapes the tumor immune microenvironment: molecular mechanisms, immune regulation, and therapeutic synergistic strategies. Front Immunol. 2026;17:1772259.
76. Li M, Liu Y, Zhang Y, Yu N, Li J. Sono-activatable semiconducting polymer nanoreshapers multiply remodel tumor microenvironment for potent immunotherapy of orthotopic pancreatic cancer. Adv Sci (Weinh). 2023;10:e2305150.
77. Gao J, Wang WQ, Pei Q, Lord MS, Yu HJ. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin. 2020;41:986-94.
78. Humeau J, Sauvat A, Cerrato G, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med. 2020;12:e11622.
79. Liu P, Zhao L, Pol J, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019;10:1486.
80. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860-75.
81. McNulty S, Colaco CA, Blandford LE, Bailey CR, Baschieri S, Todryk S. Heat-shock proteins as dendritic cell-targeting vaccines - getting warmer. Immunology. 2013;139:407-15.
82. Shen X, Fan S, He J, et al. Designer solid self-emulsifying nanovaccines enable dual modulation of dendritic cells and t cells for potent antitumor immunity. Adv Sci (Weinh). 2026;13:e12139.
83. Chen G, Wang Y, Mo L, et al. Ultrasound-activatable in situ vaccine for enhanced antigen self- and cross-presentation to overcome cancer immunotherapy resistance. ACS Nano. 2024:20296-312.
84. Zhou Y, Shen G, Zhou X, Li J. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther. 2025;10:178.
85. Wang Y, Ma J, Liu Y, et al. Unraveling the complex role of tumor-associated neutrophils within solid tumors. Cancer Immunol Immunother. 2025;74:210.
86. Gao X, Xu M, Xiao H, et al. Tumor-associated neutrophils: a complex role in cancer. Clin Immunol. 2025;280:110558.
87. Huang X, Nepovimova E, Adam V, et al. Neutrophils in cancer immunotherapy: friends or foes? Mol Cancer 2024;23:107.
88. Michelet X, Dyck L, Hogan A, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018;19:1330-40.
89. Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85-100.
90. Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401.
91. Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359-67.
92. Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635-47.
93. Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54:2701-11.
94. Topchyan P, Lin S, Cui W. The role of CD4 T cell help in CD8 T cell differentiation and function during chronic infection and cancer. Immune Netw. 2023;23:e41.
95. Lee JM. Cancer sono-immunotherapy using a multi-metal-ligand framework. Commun Mater. 2024;5:671.
96. Oliveira G, Stromhaug K, Klaeger S, et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021;596:119-25.
97. Rosato PC, Wijeyesinghe S, Stolley JM, Masopust D. Integrating resident memory into T cell differentiation models. Curr Opin Immunol. 2020;63:35-42.
98. Yu N, Zhou J, Ding M, Li M, Peng S, Li J. Sono-triggered cascade lactate depletion by semiconducting polymer nanoreactors for cuproptosis-immunotherapy of pancreatic cancer. Angew Chem Int Ed Engl. 2024;63:e202405639.
99. Guo Y, Wang SZ, Zhang X, et al. In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses. Nat Commun. 2022;13:6534.
100. Hirschhorn D, Budhu S, Kraehenbuehl L, et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023;186:1432-1447.e17.
101. Zhang C, Huang J, Zeng Z, et al. Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy. Nat Commun. 2022;13:3468.
102. Wang HH, Nan LY, Zheng Y, Guo J. Porphyrin oriented bimetallic sonodynamic MOF for enhanced ferroptosis and cGAS-STING pathway mediated antitumor immunotherapy. J Nanobiotechnology. 2026;24.
103. Zeng J, Yan Z, Wang D, et al. Mitochondria-targeted MXene@MnO2-TPP nanoheterostructures for synergistic enhancement of sonodynamic therapy and immunotherapy in osteosarcoma. Bioact Mater. 2025;54:450-65.
104. Li J, Yue Z, Tang M, et al. Strategies to reverse hypoxic tumor microenvironment for enhanced sonodynamic therapy. Adv Healthc Mater. 2024;13:e2302028.
105. Xu M, Hu Y, Wu J, Liu J, Pu K. Sonodynamic nano-LYTACs reverse tumor immunosuppressive microenvironment for cancer immunotherapy. J Am Chem Soc. 2024;146:34669-80.
106. Feng Z, Wang Z, Xiang X, et al. Progress in nanomedicine for sonodynamic immunotherapy of tumors. EngMedicine. 2024;1:100027.
107. Knight Z, Ruiz A, Elies J. Piezoelectric nanomaterials for cancer therapy: current research and future perspectives on glioblastoma. J Funct Biomater. 2025;16:114.
108. Ya Z, Guo S, Li Y, et al. Focused acoustic vortex-mediated sonochemotherapy for the amplification of immunogenic cell death combined with checkpoint blockade to potentiate cancer immunotherapy. Biomaterials. 2023;301:122278.
109. Li Y, Chen W, Kang Y, et al. Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity. Nat Commun. 2023;14:6973.
110. Choi Y, Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55:2308-19.
111. Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15:307.
112. Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174-86.
113. Yuan J, Ye D, Chen S, Chen H. Therapeutic ultrasound-enhanced immune checkpoint inhibitor therapy. Front Phys. 2021;9:636985.
114. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188-205.
115. Yu N, Li M, Zhang Y, et al. Dual-modulation of immunosuppressive pathways using sono-activatable semiconducting polymer nanofeedbacks for cancer immunotherapy. Nano Today. 2023;52:101944.
116. Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652-69.
117. Tselikas L, Susini S, Texier M, et al. Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1. Nature. 2026;655:219-29.
118. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126:2404-11.
119. Lei J, Zhang W, Ma L, et al. Sonodynamic amplification of cGAS-STING activation by cobalt-based nanoagonist against bone and metastatic tumor. Biomaterials. 2023;302:122295.
120. Wang W, Hu Q, Wu C, et al. A ferroptosis-based intelligent nanoplatform with chemo-sonodynamic therapy carrying oxygen for improving tumor suppression and antitumor immunity. J Nanobiotechnology. 2026;24.
122. Yin Y, Jiang X, Sun L, et al. Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma. Nano Today. 2021;36:101009.
123. Wang F, Dong G, Ding M, Yu N, Sheng C, Li J. Dual-programmable semiconducting polymer NanoPROTACs for deep-tissue sonodynamic-ferroptosis activatable immunotherapy. Small. 2024;20:e2306378.
124. Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531-50.
125. Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31:311-25.
126. Wan W, Han W, Chen J, et al. Chemokine-based injectable navigation system for enhancing CAR‐T cell therapy against solid tumors. Adv Funct Mater 2024;34:2401161.
127. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18:168-82.
128. Labib S, Bright RK, Liu J. Focused ultrasound in cancer immunotherapy: a review of mechanisms and applications. Ultrasound Med Biol. 2025;51:1-14.
129. Zhang P, Xiao Y, Sun X, et al. Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects. Med. 2023;4:147-67.
130. Sadeghi-Goughari M, Rajabzadeh H, Han JW, Kwon HJ. Artificial intelligence-assisted ultrasound-guided focused ultrasound therapy: a feasibility study. Int J Hyperthermia. 2023;40:2260127.
131. Zhang Y, Li J, Pu K. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy. Biomaterials. 2022;291:121906.
132. Xie Z, Duo Y, Fan T, et al. Light-induced tumor theranostics based on chemical-exfoliated borophene. Light Sci Appl. 2022;11:324.
133. Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol. 2022;35:23-32.
134. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541-50.
